Ahmed A. Othman, PhD, FCP

Clinical Pharmacology Sciences
Gilead Sciences Inc

Poster(s):

• 061: First-in-Human Evaluation of Pharmacokinetics & Safety of Tilpisertib Fosmecarbil, an Oral Prodrug of a Tumor Progression Locus 2 Inhibitor, in Healthy Volunteers
  Sunday, September 8, 2024

  5:00 PM – 7:00 PM ET

• 113: Pharmacokinetics, Safety & Tolerability of GS-1427, a Pro-drug of a Potent & Selective Small-Molecule α4β7 Integrin Inhibitor, in Healthy Volunteers
  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET

• 154: Pharmacokinetics of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors
  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET

• 156: Comparable Pharmacokinetics of Sacituzumab Govitecan Between Patients With Metastatic Urothelial Cancer & Metastatic Triple-Negative Breast Cancer
  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET